EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

From Prediction to Decision Making: PBPK and QSP as Regulatory‐Grade NAMs

Karen Rowland Yeo iD, Piet H van der Graaf iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70483 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Karen Rowland Yeo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Certara UK Limited (MID3 Division), Sheffield, UK. Hauptthemen laut MEDLINE: Models, Biological, Drug Development, Decision Making, Systems Biology. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New approach methodologies (NAMs) encompass a diverse and rapidly evolving set of experimental and computational tools designed to generate human‐relevant mechanistic data for use in drug development and regulatory decision making. Experimental NAMs provide insights into drug disposition, pharmacological activity, and disease biology that are difficult or impossible to obtain from traditional animal‐based models. Physiologically based pharmacokinetic (PBPK) and quantitative systems pharmacology (QSP) models represent a complementary class of computational NAMs. Together, experimental and computational NAMs form an integrated translational framework that converts mechanistic biological data into quantitative predictions of human exposure, efficacy, and safety across the drug development continuum. In this state‐of‐the‐art review, we present our perspective on the current and emerging role of PBPK and QSP as computational NAMs, supported by case studies spanning a range of regulatory and clinical applications. Across all case studies, the integration of human‐relevant experimental data into mechanistic models is shown to be the critical determinant of translational success. We also discuss the evolving regulatory landscape for NAMs, including the recent FDA draft guidance on QSP‐based MABEL determination, and the ICH M15 framework for model‐informed drug development. Collectively, these developments signal a fundamental shift in how mechanistic models are positioned within drug development and regulatory decision making: not as alternatives to animal testing alone, but as quantitative decision‐support frameworks that generate the human‐relevant evidence needed to support safer, more effective, and more equitable medicines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, BiologicalDrug DevelopmentDecision MakingSystems BiologyHumansAnimalsPharmacokineticsUnited StatesComputer SimulationUnited States Food and Drug Administration

Autor:innen und Institutionen

  • Certara UK Limited (MID3 Division), Sheffield, UK.
  • Leiden Academic Centre for Drug Research, Leiden, The Netherlands.
  • Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

ORCID-Profile: Karen Rowland Yeo, Piet H van der Graaf

Zitieren

APA

Rowland Yeo, K., & van der Graaf, P. H. (2026). From Prediction to Decision Making: PBPK and QSP as Regulatory‐Grade NAMs. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70483

Vancouver

Rowland Yeo K, van der Graaf PH. From Prediction to Decision Making: PBPK and QSP as Regulatory‐Grade NAMs. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70483

BibTeX
@article{RowlandYeo2026,
  author = {Rowland Yeo, Karen and van der Graaf, Piet H},
  title = {From Prediction to Decision Making: PBPK and QSP as Regulatory‐Grade NAMs},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70483}
}
Kostenlos starten →